首页> 外国专利> Nucleotide sequence, short interfering nucleotide sequence, pharmaceutical composition, method for identifying a cancerous state in a cell, kit for identifying a cancerous state in a cell, cancer treatment method and polypeptide

Nucleotide sequence, short interfering nucleotide sequence, pharmaceutical composition, method for identifying a cancerous state in a cell, kit for identifying a cancerous state in a cell, cancer treatment method and polypeptide

机译:核苷酸序列,短干扰核苷酸序列,药物组合物,用于鉴定细胞中癌态的方法,用于鉴定细胞中癌态的试剂盒,癌症治疗方法和多肽

摘要

Provided is a novel Fer-like protein, referred to as FerC (Fer colorectal cancer). FerC is a 47kDa protein having a unique N-terminal sequence and was found to be present in six colon cancer cell-lines and in five hepatocarcinoma (liver cancer) cell-lines, but not in CCD33 normal colon epithelial cells or normal human and mouse fibroblasts. Depletion of FerC impairs cell-cycle progression and induces apoptotic death in treated colon cancer (CC) cells. Also provided are nucleotide sequences that are antisense to at least a portion of the N-terminal sequence, short interfering nucleotides including such an antisense sequence, as well as pharmaceutical compositions containing an antisense sequence. The present pharmaceutical composition may be used in the treatment of cancer, in particular, colorectal cancer and liver cancer.
机译:提供了一种新型的Fer样蛋白,称为FerC(大肠直肠癌)。 FerC是一种具有独特N端序列的47kDa蛋白,被发现存在于六个结肠癌细胞系和五个肝癌(肝癌)细胞系中,但不存在于CCD33正常结肠上皮细胞或正常人和小鼠中成纤维细胞。 FerC的消耗会削弱细胞周期进程,并在治疗的结肠癌(CC)细胞中诱导凋亡性死亡。还提供了与N末端序列的至少一部分反义的核苷酸序列,包括这种反义序列的短干扰核苷酸,以及包含反义序列的药物组合物。本发明的药物组合物可以用于治疗癌症,特别是结肠直肠癌和肝癌。

著录项

  • 公开/公告号BRPI0905948A2

    专利类型

  • 公开/公告日2015-06-30

    原文格式PDF

  • 申请/专利权人 URIFER LTD;

    申请/专利号BR2009PI05948

  • 发明设计人 URI NIR;ADAR MAKOVSKI;SALLY SHPUNGIN;

    申请日2009-02-05

  • 分类号A61P35;C12N15/113;

  • 国家 BR

  • 入库时间 2022-08-21 15:16:02

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号